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extrapolated for the years 2012-2016 by applying population forecasts from the
official Finnish statistics. Health care resource use and Finnish unit costs (€2011,
societal perspective) were obtained from published national sources. RESULTS:
Approximately 35% of the 2.2 million Finns of over 50 years of age can be consid-
ered to be at moderate or high risk for PDs due to the underlying chronic medical
conditions. The vaccination of these people with PCV13 could provide an estimated
net budget savings of about €218 million compared to the current no-vaccination
situation during the five years. Among the risk groups considered, the largest net
savings (€66.2 million) could be expected to be obtained by vaccinating people with
heart disease due to its high prevalence in the target population. CONCLUSIONS:
The immunization of adults (50 years) at higher PD-risk with PCV13 vaccine will
potentially lead to substantial cost savings during the forthcoming years in Fin-
land.
PIN23
ECONOMIC ANALYSIS OF ATAZANAVIR AS 1ST LINE TREATMENT FOR VIH
PATIENTS, ON STABLE AND SEVER HEALTH STATE
Betegon L1, Hidalgo A2, Villoro R3, Ivanova A4, Woolmore A5
1Bristol-Myers Squibb, Madrid, Spain, 2Castilla-La Mancha University, Toledo, Spain, 3Instituto
Max weber, Majadahonda, MADRID, Spain, 4Instituto Max Weber, Majadahonda, Madrid, Spain,
5Monitor Group Europe, Paris, Paris, France
OBJECTIVES: To estimate the budget impact associated with use of Atazanavir as
1st line treatment in Spanish market of antiretroviral drugs for VIH patients, on
stable and sever health state. METHODS: An economic Model was developed to
evaluate the Budget Impact of using Atazanavir (ATV), as 1st line treatment, for VIH
patients in the Spanish National Health System perspective, over a 10-year period.
Therapies included in the analysis were Darunavir (DRV), Lopinavir (LPV) and Efa-
virenz (EFV). Patient data were obtained through microsimulation model, with a
patient cohort simulated, statistically significant and representative (N 40,000).
The costs were obtained from local databases and were considered pharmaceutical
and direct health care costs. An annual discount rate assumed was of 3%.The
discontinuation rates after AEs assumed for all treatments were: 71.3% from diar-
rhea, 61.3% from nausea, 28.8% from jaundice, 82.5% from rash and 55% from CNS
events. The results of BIM per patient were presented at annual and cumulative
level. RESULTS: Atazanavir use led to differential annual costs per patient after 10
years of treatment of 595€, 209€ and 76€, with respect to DRV, LPV and EFV. The
highest savings generated by ATV derived from durable health of 1st line treatment
(807€ DRV, 909€ LPV and 1045€ EFV), followed by return to health and durable viral
suppression. This savings offset ATV drug cost versus other antiretroviral drugs.
CONCLUSIONS: This analysis showed that treatment with Atazanavir for VIH pa-
tients, on stable and sever health state, generates net savings for Spanish National
Health System: 595€, 209€ and 76€, with respect to DRV, LPV and EFV, in terms of
differential annual costs per patient after 10 years treatment.
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OBJECTIVES: Recently, 13-valent Pneumococcal Conjugate Vaccine (PCV13) has
been approved for adults 50 years of age and older for the prevention of invasive
pneumococcal disease (IPD) caused by the vaccine serotypes. This study was aimed
to assess the clinical and economic impact of PCV13 use in adults with immuno-
compromising conditions based on HIV published data. METHODS: A budget im-
pact model for the whole HIV population was designed under the Spanish National
Health System with a 4-year time horizon. Calculations of cases were based on the
published IPD incidence (0.74%) and recurrent IPD ratio in this population. From
total IPD cases, 92% were considered bacteraemia originating from pneumonia,
5.5% bacteraemia without apparent focus and endocarditis and 2.5% meningitis.
PCV13 efficacy, serotype coverage, IPD mortality and disease related costs were
based on published data. Model was built up assuming full vaccination coverage
and no indirect effect. All costs were expressed in €2012. RESULTS: There would be
2,392 IPD cases in Spanish HIV patients over 4-year time horizon (598 annual cases).
The model predicts that the implementation of a PCV13 vaccination program for
HIV population would be a cost saving measure due to IPD cases averted. Over the
study period, PCV13 would prevent 646 IPD cases and 162 related deaths.
CONCLUSIONS:Based on this health economic evaluation, the inclusion of a PCV13
vaccination program for HIV population would be an efficient measure. PCV13
vaccination would have a high impact on pneumococcal disease prevention, avoid-
ing deaths and saving costs.
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OBJECTIVES: Separation of sick dairy cows to hospital pens, isolated from healthy
cows, is frequently used to manage risks of inadvertently meat and milk residue
violations associated with use of certain antimicrobials. However, drawbacks of
hospital pen moves are frequently overlooked.Our objective was to develop a
model 1) to quantify health and economic burden associated with hospital pen
moves, and 2) to compare the economic impact associated with choice of antimi-
crobials requiring a hospital pen move because of milk withholding (standard:
ampicillin, penicillin, oxytetracycline) to those not requiring milk withholding
(comparator: three ceftiofurs) and therefore avoiding hospital pen moves.
METHODS: A decision tree was developed in MS Excel to 1) estimate the impact of
hospital pen moves by considering extra labor, stress-induced reduction in milk
yield and immunity, risk of secondary diseases and associated treatment/culling/
replacement costs, and 2) compare standard and comparator treatments by con-
sidering treatment duration, milk withholding-associated revenue losses (based
on product labels) and impact of hospital pen moves. Costs and prices ($US, 2010:
producer’s perspective), risk data, and labor data were derived from published
sources. RESULTS: The economic burden of a hospital pen stay of 5 days was
estimated at $111.85/cow, mainly attributable to risk and costs of secondary dis-
eases. Ceftiofur prices ($29.33 to $107.99/cow) were generally higher than standard
antibiotics ($2.00 to $30.95/cow). However, incremental net income with ceftiofurs
compared to standard antibiotics ranged from $85.81 to $208.21/cow, the result of
withholding-associated reduced saleable milk ($51.00 to $71.40/cow) and addi-
tional costs of hospital pen moves ($111.85 to $156.34/cow) with standard
treatment. CONCLUSIONS: Compared to therapeutic treatments requiring milk
withholding and a hospital pen move, ceftiofurs’ higher prices were more than
offset by higher returns resulting from increased saleable milk and no additional
costs associated with hospital pen moves, and overall resulted in higher net in-
come for producers.
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OBJECTIVES: Antimicrobial resistance is a growing problem associated with many
bacterial infections. The problem of resistance is related to the use of antibiotics.
There is a causal relationship between antibiotic use and resistance which results
in decreased antibiotic effectiveness. Antimicrobial resistance varies among hos-
pitals significantly and results in a different financial burden due to cost-drivers
related to treatment failure including all medication costs, increased length of
hospital stay and additional medical resource consumption. Our objective was to
estimate the real life effectiveness of using different antibiotics in a certain hospi-
tal by analyzing the total cost of therapy during hospitalization. METHODS: A
cost-offset model was developed to support the individual therapeutic decisions of
hospitals. We analyzed a 6 months time period and a number of 59 complicated
intra-abdominal infection (IAI) episodes in a Hungarian county hospital retrospec-
tively. Based on the first antibiotic choice we defined different treatment pathways
to compare the length of stay and the total cost of the hospitalization in each
treatment arm. RESULTS: The average length of stay (LOS) with complicated IAI
was 5 days and increased to 8.6 days due to any adverse events. If the first antibiotic
treatment was not effective - means that the patient had to switched to another
antibiotic drug - the average LOS increased to 9.5 days. The cost difference of the
different antibiotic drugs ranged from 121% to 391% compared to the cheapest
treatment. The total hospitalization cost in case of the most expensive antibiotic
treatment was higher by an average of 8% compared to the total cost of the cheap-
est antibiotic drug treatment. CONCLUSIONS: In long term the impact of resis-
tance, the choice of adequate antibiotic therapy, the infection-control and the need
for real-life effectiveness analysis because of budgetary reasons are increasingly
important for hospitals.
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OBJECTIVES: We performed an economic evaluation of voriconazole vs liposomal
amphotericin B as first-line antifungals for invasive aspergillosis (IA) among pa-
tients with prolonged neutropenia or undergoing bone marrow or hematopoietic
stem-cell transplantation from a German hospital perspective. METHODS: A deci-
sion analytic model was constructed to estimate potential treatment costs of vori-
conazole vs liposomal amphotericin B. Each pathway was defined by probabilities
of an event and costs of clinical outcomes. Probabilities and costs were derived
from literature, clinical trials, and expert panels. In the base case, patients who
failed first-line therapy were assumed to experience a single switch between com-
parator drugs or add on the other drug as second-line treatment. Base-case evalu-
ation included drug management costs and additional hospitalization costs due to
severe adverse events. Sensitivity analyses were conducted to assess robustness of
results. All costs were inflated to 2011 Euros. RESULTS: Based on clinical trial suc-
cess rates of 52.8% (voriconazole) and 50% (liposomal amphotericin B), and length
of treatment (LOT)  10-day intravenous (IV)  5-day oral for voriconazole and
15-day IV for liposomal amphotericin B, voriconazole had a lower total treatment
cost than liposomal amphotericin B (€12,256 vs €18,133). Assuming the same effi-
cacy (50%) in first-line therapy, voriconazole still had a lower total treatment cost
than liposomal amphotericin B (€12,837 vs €18,133). Assuming the same LOT (10 or
15 days) in both arms, voriconazole maintained a lower cost. Cost savings were
primarily due to lower drug costs and shorter IV LOT associated with voriconazole.
The model was sensitive to drug prices and hospital per day costs. CONCLUSIONS:
This study suggests that voriconazole is likely to be cost-saving compared to lipo-
somal amphotericin B in the treatment of IA from the German hospital perspective.
A389V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
